Literature DB >> 30964519

Nurse Practitioner and Physician Assistant Waivers to Prescribe Buprenorphine and State Scope of Practice Restrictions.

Joanne Spetz1, Christopher Toretsky1, Susan Chapman2, Bethany Phoenix3, Matthew Tierney3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30964519      PMCID： PMC6459110          DOI： 10.1001/jama.2019.0834

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  17 in total

1.  A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.

Authors:  Katharine Cioe; Breanne E Biondi; Rebecca Easly; Amanda Simard; Xiao Zheng; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2020-09-22

Review 2.  Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers within the Treatment System.

Authors:  Bertha K Madras; N Jia Ahmad; Jenny Wen; Joshua Sharfstein Sharfstein
Journal:  NAM Perspect       Date:  2020-04-27

Review 3.  Assessment of State and Federal Health Policies for Opioid Use Disorder Treatment During the COVID-19 Pandemic and Beyond.

Authors:  Seema Choksy Pessar; Anne Boustead; Yimin Ge; Rosanna Smart; Rosalie Liccardo Pacula
Journal:  JAMA Health Forum       Date:  2021-11-19

4.  In Rural Areas, Buprenorphine Waiver Adoption Since 2017 Driven By Nurse Practitioners And Physician Assistants.

Authors:  Michael L Barnett; Dennis Lee; Richard G Frank
Journal:  Health Aff (Millwood)       Date:  2019-12       Impact factor: 6.301

5.  Buprenorphine waiver uptake among nurse practitioners and physician assistants: The role of existing waivered prescriber supply.

Authors:  Samantha G Auty; Michael D Stein; Alexander Y Walley; Mari-Lynn Drainoni
Journal:  J Subst Abuse Treat       Date:  2020-05-13

6.  Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing.

Authors:  Barbara Andraka-Christou; Adam J Gordon; Joanne Spetz; Rachel Totaram; Matthew Golan; Olivia Randall-Kosich; Jordan Harrison; Spencer Calder; Stefan G Kertesz; Bradley D Stein
Journal:  J Subst Abuse Treat       Date:  2022-01-10

Review 7.  Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA.

Authors:  Amanda J Abraham; Christina M Andrews; Samantha J Harris; Peter D Friedmann
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

8.  The Association Between Scope of Practice Regulations and Nurse Practitioner Prescribing of Buprenorphine After the 2016 Opioid Bill.

Authors:  Thuy Nguyen; Ulrike Muench; Barbara Andraka-Christou; Kosali Simon; W David Bradford; Joanne Spetz
Journal:  Med Care Res Rev       Date:  2021-04-01       Impact factor: 3.929

9.  It will end in tiers: A strategy to include "dabblers" in the buprenorphine workforce after the X-waiver.

Authors:  Brendan Saloner; Barbara Andraka Christou; Adam J Gordon; Bradley D Stein
Journal:  Subst Abus       Date:  2021-04-02       Impact factor: 3.716

10.  Disparities in receipt of medications for opioid use disorder among pregnant women.

Authors:  Laura E Henkhaus; Melinda B Buntin; Sarah Clark Henderson; Pikki Lai; Stephen W Patrick
Journal:  Subst Abus       Date:  2021-07-16       Impact factor: 3.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.